沙库巴曲缬沙坦钠片联合常规治疗对肺源性心脏病合并心力衰竭患者心脏功能储备的影响

Effect of Sacubitril Valsartan Sodium Tablets Combined with Conventional Treatment on Cardiac Function Reserve in Patients with Pulmonary Heart Disease Complicated with Heart Failure

目的:探讨沙库巴曲缬沙坦钠片联合常规治疗对肺源性心脏病合并心力衰竭患者心脏功能储备的影响。方法:选取2018年3月-2021年3月中国人民武装警察部队海南省总队医院收治的125例肺源性心脏病合并心力衰竭患者,根据治疗方法将其分为观察组(n=72)和对照组(n=53)。对照组予以常规治疗,观察组予以沙库巴曲缬沙坦钠片联合常规治疗。比较两组总有效率、心脏功能储备指标[左心室射血分数(LVEF)、6分钟步行距离(6MWT)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、炎症因子[超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、细胞间黏附分子-1(ICAM-1)]及安全性。结果:观察组总有效率为90.28%,高于对照组的75.47%(P<0.05)。观察组LVEF、6MWT水平均高于对照组,而LVEDD、LVESD、hs-CRP、IL-6、TNF-α、ICAM-1水平均低于对照组(P<0.05)。观察组不良反应发生率为6.94%,低于对照组的26.42%,差异有统计学意义(P<0.05)。结论:沙库巴曲缬沙坦钠片联合常规治疗肺源性心脏病合并心力衰竭患者不仅可提高临床效果,还可显著逆转心室重构,提高运动耐量,且安全性高,预后效果好,临床应用价值高。

Objective:To explore the effect of Sacubitril Valsartan Sodium Tablets combined with conventional treatment on cardiac function reserve in patients with pulmonary heart disease complicated with heart failure.Method:A total of 125 patients with pulmonary heart disease complicated with heart failure admitted to Hainan Provincial Corps Hospital of the Chinese People’s Armed Police Force from March 2018 to March 2021 were selected,they were divided into observation group(n=72)and control group(n=53)according to treatment methods.The control group was given conventional treatment,and the observation group was given Sacubitril Valsartan Sodium combined conventional treatment.The total effective rate,cardiac reserve function indexes[left ventricular ejection fraction(LVEF),6-minute walking test(6MWT),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],inflammatory factors[hypersensitive C reactive protein(hs-CRP),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α),intercellular adhesion molecule-1(ICAM-1)]and safety were compared between the two groups.Result:The total effective rate in the observation group was 90.28%,which was higher than 75.47%in the control group(P<0.05).The levels of LVEF and 6MWT in the observation group were higher than those in the control group,while the levels of LVEDD,LVESD,hs-CRP,IL-6,TNF-αand ICAM-1 in the observation group were lower than those in the control group(P<0.05).The incidence of adverse reactions was 6.94%in the observation group,which was lower than 26.42%in the control group,the difference was statistically significant(P<0.05).Conclusion:Sacubitril Valsartan Sodium combined with conventional treatment of patients with pulmonary heart disease combined with heart failure can not only improve the clinical effect,but also significantly reverse ventricular remodeling and improve exercise tolerance,with high safety,good prognostic effect and high clinical application value.